Company Filing History:
Years Active: 2017-2018
Title: Hyojin Lim: Innovator in Histone Deacetylase Inhibitors
Introduction
Hyojin Lim is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of selective histone deacetylase (HDAC) inhibitors. With a total of 2 patents, his work focuses on innovative compounds that have the potential to treat various diseases.
Latest Patents
Hyojin Lim's latest patents include two groundbreaking inventions. The first patent involves compounds for selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same. This invention provides urea derivatives of Formula I, which exhibit HDAC inhibitory activity. These compounds are effective in treating histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, and neurodegeneration.
The second patent features azaindole derivatives as selective histone deacetylase inhibitors. This invention relates to novel azaindole derivatives that possess HDAC inhibitory activity. The patent outlines the use of these derivatives for preparing pharmaceutical compositions aimed at treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.
Career Highlights
Hyojin Lim is currently associated with Chong Kun Dang Pharmaceutical Corporation, where he continues to advance his research and development efforts. His work has garnered attention in the pharmaceutical industry, particularly for its potential therapeutic applications.
Collaborations
Hyojin Lim has collaborated with notable colleagues, including ChangSik Lee and Hyun-Mo Yang. These partnerships have contributed to the successful development of his innovative compounds.
Conclusion
Hyojin Lim's contributions to the field of histone deacetylase inhibitors highlight his role as a significant inventor in pharmaceutical sciences. His innovative patents pave the way for new treatments for serious diseases, showcasing the importance of research and collaboration in advancing medical science.